Lenalidomide as second‐line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy - Shao, Y.‐Y.; Chen, B.‐B.; Ou, D.‐L.; Lin, Z.‐Z.; Hsu, C.‐H.; Wang, M.‐J.; Cheng, A.‐L.; Hsu, C. (Alimentary pharmacology & therapeutics, 2017)
Keywords: Adult; Aged; alpha-Fetoproteins - metabolism; Angiogenesis; Angiogenesis Inhibitors - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biomarkers; Biomarkers, Tumor - metabolism; Carcinoma, Hepatocellular - drug therapy; Disease control; Disease Progression; Disease-Free Survival; Female; Hepatocellular carcinoma; Humans; Immunomodulation; Immunotherapy; Liver cancer; Liver Neoplasms - drug therapy; Lymphocytes B; Magnetic resonance imaging; Male; Middle Aged; Niacinamide - administration & dosage; Niacinamide - analogs & derivatives; Peripheral blood; Phenylurea Compounds - administration & dosage; Survival; Targeted cancer therapy; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Treatment Outcome; Tumors